MedTrace Logo

A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors

NCT05810103 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-04-12

No results posted yet for this study

Summary

This is a study of DP303c in patients with HER2-positive advanced solid tumors.

Conditions

  • HER2-positive Advanced Solid Tumors

Interventions

DRUG

DP303c

DP303c injection, 3.0 mg/kg, every 3 weeks.

Sponsors & Collaborators

  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-06
Primary Completion
2023-12-23
Completion
2024-03-23

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05810103 on ClinicalTrials.gov